Term
Prostate cancer treatment for locally advances |
|
Definition
radiation + hormone (goselin) |
|
|
Term
what regimen for locally advanced prostate |
|
Definition
|
|
Term
Prostate positive DRE, how to responde |
|
Definition
always TRUS and biopsy. also, always perform TRUS and biopsy w/PSA > 10 |
|
|
Term
|
Definition
2-4, well differentiated, 5-6, moderate margins, 7-10 poorly differentiated |
|
|
Term
prostate cancer treatment for metastatic disease |
|
Definition
palliative care: hormone deprivation w/antiandrogens or LHRH agonists/antagonists |
|
|
Term
palliative care with antiandrogens (overview) |
|
Definition
most effective in combination therapy, reduces flare risk, |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
non steroidal antiandrogen |
|
|
Term
|
Definition
non steroidal antiandrogen |
|
|
Term
|
Definition
non steroidal antiandrogen; many SE, not used often |
|
|
Term
|
Definition
LHRH antagonist; reduces testosterone to castration levels, can cause QT prolongation; no risk of tumor flare |
|
|
Term
definition of hormone refractory prostate cancer |
|
Definition
increasing PSA or symptomatic progression |
|
|
Term
supportive care in hormone refractory prostate cancer |
|
Definition
prednisone and/or dexamethasone |
|
|
Term
hormone refractory prostate cancer regimens w/prednisone |
|
Definition
mitoxantrone, docetaxel, cazitaxel |
|
|
Term
hormone refractory prostate cancer regimens w/estramustine |
|
Definition
vinblastine, etoposide, docetaxel, |
|
|
Term
hormone refractory prostate cancer regimens w/o prednisone or estramustine |
|
Definition
ketoconazole and doxorubicin; sipuleucel-T (Immunotherapy) |
|
|
Term
|
Definition
anthracenedione; dose adjust on hepatic function; can cause cardiac events |
|
|
Term
|
Definition
nitrogen-mustard-estradiol; inhibits microtubules; can cause fluid retention, gynecomastia |
|
|
Term
preferred regimen in hormone resistant prostate cancer |
|
Definition
docetaxel,prednisone, bevacizumab |
|
|
Term
|
Definition
immunotherapy; autologous CD 54+; for minimally symptomatic refractory prostate cancer |
|
|
Term
|
Definition
microtubule inhibitor; premedicate w/diphenhydramine, dexamethasone, ranitidine; approved for docetaxel failed patients |
|
|
Term
|
Definition
platinum-based chemo; no renal impairment or neuropathy; limited myelosuppression; for refractory prostate cancer, no survival benefit but superior time to progression |
|
|
Term
tx for bone metastasis in prostate cancer |
|
Definition
zolendronic acid or denosumab |
|
|
Term
|
Definition
surgery or radiation, survival 67% |
|
|
Term
|
Definition
surgery w/chemo; survival ~ 40% |
|
|
Term
NSCLC stage III resectable tx |
|
Definition
surgery w/chemo; survival ~ 20% |
|
|
Term
NSCLC stage III non-resectable or stage IV tx |
|
Definition
chemradiotherapy or chemotherapy; survival ~ 3% |
|
|
Term
indication for radiotherapy in NSCLC |
|
Definition
postoperative w/positive margins; chemoradiotherapy in unresectable stage III |
|
|
Term
chemotherapy indications in NSCLC |
|
Definition
stage II and IIIa w/cisplatin-based regimen |
|
|
Term
preferred chemo regimen in NSCLC |
|
Definition
|
|
Term
NSCLC stage IIIb non-resectable preferred regimen |
|
Definition
cisplatin/etoposide w/radiotherapy |
|
|
Term
how to treat NSCLC stage IIIb nonresectable w/pleural effusion |
|
Definition
follow stage IV guidelines |
|
|
Term
NSCLC stage IV first line tx |
|
Definition
cisplatin/pemetrexed in PS 0,1 |
|
|
Term
indication for bevacizumab in stage IV NSCLC |
|
Definition
adjunct to carboplatin/paclitaxel |
|
|
Term
indication for cetuximab in NSCLC stage IV |
|
Definition
adjunct to cisplatin/vinorelbine in EGFR-positive tumor |
|
|
Term
when is erlotinib/gefitinib 1st line in NSCLC stage IV |
|
Definition
in patients w/EGFR mutations regardless of PS |
|
|
Term
NSCLC tx in PS 2,3,4 stage IV |
|
Definition
single regimen tx in PS 2, no chemo in >2 |
|
|
Term
second line tx for NSCLC stage IV |
|
Definition
docetaxel or pemetrexed or erlotinib, may want to reserve erlotinib for 3rd line |
|
|
Term
which genetic marker is routinely checked in NSCLC |
|
Definition
EGFR which is overexpressed in 80% |
|
|
Term
best time to progression among NSCLC IIIb or IV tx |
|
Definition
cisplatin and gemcitabine; also highest rate of thrombocytopenia |
|
|
Term
1st line for NSCLC squamous cell |
|
Definition
|
|
Term
|
Definition
for locally advanced or metastatic non-squamous NSCLC; contraindicated CrCl<45; coadminister folic acid + B12 |
|
|
Term
|
Definition
dose limiting nephrotoxicity, administer w/significant fluids, contraindicated Cr > 1.5; N/V; |
|
|
Term
|
Definition
dose-limiting myelosuppression |
|
|
Term
|
Definition
-25% dose if CrCl<50; -50% if CrCl<10 |
|
|
Term
|
Definition
|
|
Term
|
Definition
fluid retention; avoid if bilirubin >1.5 |
|
|
Term
|
Definition
elevates liver enzymes; relative contraindication in severe hepatic/renal |
|
|
Term
|
Definition
reduce dose by 1/2 if bilirubin >2, by 75% if bilirubin >3 |
|
|
Term
|
Definition
contraindicated w/bleed risk (hemoptysis); add to carboplatin/paclitaxel for OS and RR (bleed risk); contraindicated w/squamous cell; CNS metastasis |
|
|
Term
indication for cetuximab in NSCLC |
|
Definition
IIIb and IV w/cisplatin and vinorelbine; rash predicted of better outcome |
|
|
Term
|
Definition
indicated for all EGFR mutation(?); may cause hepatic failure; gefitinib has similar efficacy |
|
|
Term
|
Definition
grade 1: hydrocortisone; grade 2: fluticasone or oral steroid for multiple rashes; grade 3: oral methylprednisolone |
|
|
Term
maintenance therapy for non-squamous NSCLC |
|
Definition
|
|
Term
maintenance therapy for squamous NSCLC |
|
Definition
|
|
Term
|
Definition
etoposide/cisplatin; etoposide/carboplatin; cyclophosphamide/doxyrubicin/vincristine; |
|
|
Term
|
Definition
topo I inhibitor; myelosuppression dose limiting; reduce dose by 50% if CrCl 20-40; approved for relapsed SCLC w/response to primary therapy 45 days out |
|
|
Term
|
Definition
cell cycle non-specific nitrogen mustard;cytotoxic, disrupts DNA; extravasation risk; sodium thiosulfate used for antidote |
|
|
Term
|
Definition
alylating agent; used for multiple myeloma |
|
|
Term
|
Definition
alkylating agent; used for chronic lymphocytic leukemia |
|
|
Term
|
Definition
|
|
Term
|
Definition
formed by ifosfamide, causes hemorrhagic cystitis |
|
|
Term
|
Definition
alkylating agent used in testicular cancer |
|
|
Term
1st line therapy for stage III colorectal cancer |
|
Definition
FOLFOX; oxaliplatin, 5-FU/leucovorin |
|
|
Term
5-FU regimen for stage III colon cancer |
|
Definition
LV/5-FU bolus days 1-5, repeat @ 4 weeks |
|
|
Term
|
Definition
converted to 5-FU enzymatically; equivalent to 5-FU in stage III colorectal cancer |
|
|
Term
|
Definition
rescue therapy for 5-FU, prevents dose limiting incorporation of 5-FU into RNA through enzymatic conversion to uridine |
|
|
Term
|
Definition
alkylating agent; used in chronic lymphoctyic leukemia |
|
|
Term
|
Definition
platinum based; generally well tolerated; causes neurotoxicity; acute 56%, resolves 2 weeks; avoid cold air/drink; if chronic need glutathione for tx |
|
|
Term
|
Definition
nitrosourea; lipophilic, cross BBB; crosslink DNA and disable repair enzyme |
|
|
Term
|
Definition
nitrosourea used in islet cell carcinoma |
|
|
Term
bevacizumab role in stage III colorectal cancer |
|
Definition
unclear, provides benefit in first two years of tx |
|
|
Term
first line tx for metastatic colorectal cancer |
|
Definition
FOLFOX + bevacizumab/switch bev to cetuximab in KRAS wild type.
oxaliplatin + irinotecan 2nd line +/- bev a couple of other options |
|
|
Term
|
Definition
topo I inhibitor; active metabolite is SN 38; ketoconazole increases this reaction, st. john's wort decreases it; infusion-related diarrhea managed w/atropine |
|
|
Term
|
Definition
|
|
Term
|
Definition
cannot be combined, cetuximab only works with native KRAS. cetuximab works well w/KRAS wild type |
|
|
Term
|
Definition
recombinant EGFR monoclonal antibody; indicated last line in wild type KRAS mCRC for improved PFS (not OS) after failure of fluoropyrimidine, oxaliplatin, irinotecan |
|
|
Term
maximum BSA for dosing chemo drugs |
|
Definition
|
|
Term
what are the risks w/intrathecal infusion |
|
Definition
drug cannot be removed or reversed once administered. always a time out for intrathecal administrations |
|
|
Term
with multidrug regimens when are taxanes administered |
|
Definition
first (pay your taxes first) |
|
|
Term
|
Definition
cisplatin, dacarbazine, dactinomycin, daunorubicin, doxorubicin, epirubicin, idrarubicin, mechlorethamine, mitomycin c, stroptazosin, vinblastine, vincristine, vindesine, vinorelbine |
|
|
Term
risk factors for extravasation |
|
Definition
age, vasculature, education, skill of practicioner, method of administration |
|
|
Term
|
Definition
avoid extremities, poorly vascularized regions, central if possible, |
|
|
Term
cisplatin remedy for extravasation |
|
Definition
|
|
Term
most likely female cancers by age |
|
Definition
<20: leukemia, <60 breast, >60 lung |
|
|
Term
pemetrexed role in stage III/IV lung cancer |
|
Definition
maintenance or initial tx w/cisplatin for non-squamous NSCLC |
|
|
Term
APL (promyelocytic acute leukemia) tx |
|
Definition
add ATRA; causes tumor lysis syndrome so monitor for coaguolopathies |
|
|
Term
1st line treatment for acute myeloid leukemia |
|
Definition
&+3 cytarabine for 7 days, anthracycline (daunorubicin, idrarubicin, mitoxantrone) for 3 days |
|
|
Term
|
Definition
|
|
Term
|
Definition
topotecan; myelosuppression, caution in renal |
|
|